Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
Details : AVB-S6-500 (batiraxcept), is an ultra-high affinity decoy protein that binds to GAS6, the ligand that activates AXL, hence inhibits the metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. It is being investigated for clear cell ...
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Inapplicable
May 16, 2023
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Batiraxcept,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVB-500 (Batiraxcept) is an ultra-high affinity decoy protein that captures GAS6, thereby potentially stopping the migration and invasion of tumor cells into healthy tissue.
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Inapplicable
April 01, 2023
Lead Product(s) : Batiraxcept,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Batiraxcept,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVB-500 (batiraxcept) is an ultra-high affinity decoy protein that captures GAS6, thereby potentially stopping the migration and invasion of tumor cells into healthy tissue.
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Inapplicable
February 28, 2023
Lead Product(s) : Batiraxcept,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVB-500 (batiraxcept), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents.
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Inapplicable
February 13, 2023
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Batiraxcept,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVB-S6-500 (batiraxcept), is an ultra-high affinity decoy protein that binds to GAS6, the ligand that activates AXL, hence inhibits the metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. It is being investigated for platinum-re...
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : Batiraxcept,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
Details : AVB-S6-500 (batiraxcept), for treatment of patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology (IO)-based and VEGF-TKI-based thera...
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Batiraxcept,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : BVF Partners
Deal Size : $41.5 million
Deal Type : Private Placement
Aravive Announces Approximately $41.5 Million Private Placement Financing
Details : Funding will be used to provide the topline readout of Phase 3 trial in PROC batiraxcept (formerly AVB-500), incremental data read outs from the Phase 1b/2 trial in clear cell renal cell cancer and expanded Phase 1b pancreatic adenocarcinoma studies anti...
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Undisclosed
October 25, 2022
Lead Product(s) : Batiraxcept,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : BVF Partners
Deal Size : $41.5 million
Deal Type : Private Placement
Lead Product(s) : Batiraxcept,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : 3D Medicines Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Aravive Receives Third Development Milestone from 3D Medicines
Details : batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, inhibiting metastasis, tumor growth, and restoring sensitivity to anti-cancer agents.
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : Batiraxcept,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : 3D Medicines Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVB-S6-500 (Batiraxcept) 15 mg/kg in combination with cabozantinib 60 mg has a manageable safety profile in previously treated ccRCC; no dose-limiting toxicities have been observed; a similar safety profile was observed across the 15 mg/kg and 20 mg/kg d...
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting
Details : Batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents.
Product Name : AVB-S6-500
Product Type : Protein
Upfront Cash : Inapplicable
April 29, 2022
Lead Product(s) : Batiraxcept,Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable